摘要
目的:探讨阿德福韦酯(ADV)对慢性乙型肝炎(CHB)患者外周血中HBcAg特异性CTL数量的影响.方法:选择应用ADV治疗48wk的HLA-A2阳性CHB患者11例作为研究对象,应用Tetramer流式细胞技术检测治疗前后PBMC中的HBcAg特异性CTL细胞频率.结果:HBcAg特异性CTL为0.074%-0.937%.CHB患者体内的特异性CTL频率远低于急性乙型肝炎.经ADV治疗CHB患者48wk后,其BcAg特异性CTL较治疗前无明显变化;亚组分析也表明无论治疗48wk后HBVDNA是否转阴、ALT是否恢复正常,对特异性CTL均无影响.结论:应用ADV治疗48wk,对CHB患者体内HBcAg特异性CTL细胞频率无明显影响.
AIM： To investigate the effect of adeforvir dipivoxil on HBcAg-specific cytotoxic T cells in patients with chronic hepatitis B （CHB）.METHODS： The frequency of circulating HB- cAg-specific cytotoxic T cells in 11 HLA-A2＋ chronic hepatitis B patients were studied longitudinally before and after adeforvir dipivoxil therapy by HLA-A2/peptide tetramer staining. RESULTS： The frequency of HBcAg-specific cytotoxic T cells ranged from 0.074% to 0.937%. The frequency of HBcAg-specific cytotoxic T cells in chronic hepatitis B patients was lower than that in acute hepatitis B patients. No significant difference was observed in the frequency of HBcAg-specific cytotoxic T cells between before and after adeforvir dipivoxil therapy. Subgroup analysis indicated that, after therapy with adeforvir dipivoxil for 48 hours, HBV DNA or ALT levels had no effect on the frequency of HBcAg- specific cytotoxic T cells. CONCLUSION： Adeforvir dipivoxil probably exerts no effect on the frequency of HBcAg- specific cytotoxic T cells in patients with CHB.
出处
《世界华人消化杂志》
CAS
北大核心
2009年第19期1996-1999,共4页
World Chinese Journal of Digestology
基金
首都医学发展科研基金资助项目
No.2003-3066~~
